key: cord-1042059-c1jlo9ny
authors: Chorin, Ehud; Dai, Matthew; Kogan, Edward; Wadhwani, Lalit; Shulman, Eric; Nadeau-Routhier, Charles; Knotts, Robert; Bar-Cohen, Roi; Barbhaiya, Chirag; Aizer, Anthony; Holmes, Douglas; Bernstein, Scott; Spinelli, Michael; Park, David; Chinitz, Larry; Jankelson, Lior
title: Electrocardiographic Risk Stratification in COVID-19 Patients
date: 2021-02-02
journal: Front Cardiovasc Med
DOI: 10.3389/fcvm.2021.636073
sha: 186b50365247a4ca95b46d2e3d53050af89240c7
doc_id: 1042059
cord_uid: c1jlo9ny

Background: The COVID-19 pandemic has resulted in worldwide morbidity at unprecedented scale. Troponin elevation is a frequent laboratory finding in hospitalized patients with the disease, and may reflect direct vascular injury or non-specific supply-demand imbalance. In this work, we assessed the correlation between different ranges of Troponin elevation, Electrocardiographic (ECG) abnormalities, and mortality. Methods: We retrospectively studied 204 consecutive patients hospitalized at NYU Langone Health with COVID-19. Serial ECG tracings were evaluated in conjunction with laboratory data including Troponin. Mortality was analyzed in respect to the degree of Troponin elevation and the presence of ECG changes including ST elevation, ST depression or T wave inversion. Results: Mortality increased in parallel with increase in Troponin elevation groups and reached 60% when Troponin was >1 ng/ml. In patients with mild Troponin rise (0.05–1.00 ng/ml) the presence of ECG abnormality and particularly T wave inversions resulted in significantly greater mortality. Conclusion: ECG repolarization abnormalities may represent a marker of clinical severity in patients with mild elevation in Troponin values. This finding can be used to enhance risk stratification in patients hospitalized with COVID-19.

Coronavirus Disease (COVID19) pandemic, induced by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is reaching now historical magnitude as one of the deadliest outbreaks in modern history (1) . As of December 30 2020, over 80 million individuals were reported to be infected by SARS-CoV-2, with more than 1.8 million deaths (2) . Recent reports (3, 4) revealed that cardiac complications are common (≈20-25%) in COVID19 infection and are associated with increased mortality. However, in those reports, "cardiac complications" were defined according to clinical and laboratory parameters (troponin levels) without systematic electrocardiographic (ECG) evaluation. It is unknown if elevations in troponin levels are reflective of a primary myocardial infarction, supply-demand inequity, or non-ischemic direct myocardial injury. The ECG is an attractive diagnostic tool as it is widely available and can be rapidly performed without inducing significant exposure of caregivers to SARS-CoV-2. ECG has been demonstrated to aid with prognostication in population-based studies (5, 6) and thus offers a particularly appealing modality during the current pandemic. We thus sought to determine whether findings on the first presenting ECG provide prognostic information and provide insights on myocardial injury. We reviewed ECGs of consecutive patients with COVID19 infection requiring hospitalization. We examined our findings stratified by troponin levels and clinical condition.

This is a retrospective study performed at NYU Langone Medical Center, New York, USA. We included 204 consecutive adult patients hospitalized at NYU Langone Medical Center with COVID19 disease. Medical records were reviewed to obtain baseline characteristics, laboratory data, and ECGs. Troponin I concentrations were assessed via the Abbott Architect method (Abbott, Abbott Park, Illinois) wherein the 99th percentile for a normal population is 0.05 ng/mL and the maximal Troponin level was recorded. Descriptive analyses were performed by troponin levels stratified into normal (0.00-0.05 ng/mL), mildly elevated (0.05-1 ng/mL), and significantly elevated (>1 ng/mL). The first, presenting ECGs were reviewed and interpreted by five senior cardiologists who were blinded to the clinical status of the patients. Data reviewed from each ECG included heart rate, rhythm categorized as normal sinus rhythm or atrial fibrillation/flutter (AF), atrioventricular block (AVB), right bundle branch block (RBBB), left bundle branch block (LBBB), a non-specific intraventricular conduction block (QRS duration >120 ms), the presence of ST segment or T-wave changes (localized ST elevation, localized T-wave inversion, or other non-specific repolarization abnormalities). The closing date of follow-up was April 15th 2020. Collected data on the closing date included arrhythmic events and mortality. The study was reviewed and approved by the NYU Institutional Review Board and Quality Improvement initiative in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments, with a waiver of informed consent.

Statistical analysis was performed using IBM SPSS Statistics 26, and figures were constructed using GraphPad Prism 8. Continuous variables are expressed as mean ± standard deviation or median (25th−75th percentile), and categorical variables are expressed as count (percentages). Normality of data samples was assessed using Shapiro-Wilk test. Two sample hypothesis testing for continuous variables was performed using Student's t-test if samples had normal distributions and Mann-Whitney U test if samples did not have normal distributions. Hypothesis testing for categorical variables was performed using Fisher's exact test. Significance testing for Kaplan-Meier curves was performed using log-rank test. For predictors of mortality, Abbreviations: ECG, Electrocardiography; COPD, Chronic obstructive pulmonary disease; CAD, Coronary artery disease; CHF, Congestive heart failure; CKD, Chronic kidney disease; HTN, Hypertension; DM, Diabetes mellitus; LFTs, Liver function tests. Figure 2) . The presence of an abnormal ECG finding resulted in significantly lower survival in the intermediate Troponin elevation group (0.05-1 ng/ml) but not in the low (<0.05 ng/ml) or high (> 1 ng/ml) Troponin elevation groups (Figure 3) 

Multiple mechanisms have been shown to explain the frequent COVID-19 induced cardiovascular injury. These include direct injury to the myocardium induced by a cytokine storm resulting from a hyperinflammatory state, microvascular damage resulting from abnormal activation of the coagulation cascade including disseminated intravascular coagulation and thrombosis, supplydemand mismatch resulting from respiratory induced tissue hypoxia in conjunction with increase in metabolic demand of infection and inflammation, and myocardial injury by direct entry of SARS-CoV-2 into cardiomyocytes expressing the ACE2 receptor (7) (8) (9) . In this retrospective cohort study we further assess the interaction of ECG abnormalities and Troponin elevation. We demonstrate that (1) myocardial injury defined by elevated Troponin is indeed prevalent in patients hospitalized with COVID-19 but is more often mild, associated with lowlevel elevation in troponin concentration. (2) more significant myocardial injury, as evident by increased Troponin level may be associated with higher risk of mortality. (3) In the group of patients with mild Troponin elevation (0.05-1 ng/ml), ECG abnormalities, and particularly T wave inversions are associated with significantly increased mortality. Consistent with our findings, a recent study had demonstrated that T wave inversion is highly frequent finding in patients with COVID-19, conferring increased risk for mortality and particularly when accompanied by Troponin elevation (10) . Though troponin elevation above the 99th percentile of the upper reference limit is considered the central marker of "myocardial injury, " mild elevation between 0.05 and 1 is often non-specific and associated with non-vascular etiologies such as strain, myocyte necrosis and increased cell membrane permeability (11) (12) (13) . Indeed, mild Troponin elevation was a frequent finding in our cohort, present in 31% of patients with COVID-19. In this regard, our data suggests that assessment for the presence of ECG abnormalities can be used to enhance inpatient risk stratification in those patients with mild Troponin elevation, with potentially intensification of monitoring and therapy. Finally, as persistent fever is a frequent clinical feature of COVID-19, as well as potential side effect of the novel vaccines, caregivers should be familiar with the phenomena of fever induced Brugada pattern and not mistake it for ST elevation myocardial infarction. For patients who present with transient, fever induced Brugada pattern, elective challenge with sodium channel blocking agent (Procainamide, Flecainide, Ajmalin) after resolution of the acute illness can establish the diagnosis of Brugada.

Our study has several limitations. This is an observational, retrospective study. Because of its retrospective nature, the study is subject to selection bias, and its results imply association, not cause and effect. Relatively short follow-up time after was available. The study was not aimed at providing mechanistic insight for the cause of repolarization changes and Troponin elevation. We did not asses structural information from echo due to limited number of tests performed. However, this study was directed at assessing the presenting ECG as a readily available tool for risk stratification in combination with Troponin, a simple blood test.

The data analyzed in this study is subject to the following licenses/restrictions: Data sharing will be considered pending request. Requests to access these datasets should be directed to lior.jankelson@nyumc.org.

The studies involving human participants were reviewed and approved by Quality Control Act With Accordance to the NYU Langone Health IRB. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

LJ and EC: concept, data collection, and manuscript. MD and EK: statistics. LW, ES, CN-R, RK, and RB-C: data collection. CB, AA, DH, SB, MS, DP, and LC: manuscript writing and review. All authors contributed to the article and approved the submitted version.

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

COVID-19) Pandemic. Geneva: World Health Organization (2020)

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in

China: a retrospective cohort study

cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)

Electrocardiographic predictors of incident congestive heart failure and all-cause mortality in post-menopausal women: the Women's Health Initiative

Association of nonspecific minor ST-T abnormalities with cardiovascular mortality: the Chicago Western electric study

Coronavirus disease 2019 (COVID-19) and cardiovascular disease

COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what is the evidence?

Potential effects of coronaviruses on the cardiovascular system: a review

Differential diagnosis of elevated troponins

T-wave inversion as a manifestation of COVID-19 infection: a case series

Trivializing an elevated troponin: adding insult to injury?

Cardiac troponins: from myocardial infarction to chronic disease

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.